Zum Inhalt springen Zur Suche springen

News-Detail

Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials.
Jeffrey A Cohen et al., Mult Scler. 2025

Jeffrey A Cohen, Douglas L Arnold, John DeLuca, Hans-Peter Hartung, Ludwig Kappos, Giancarlo Comi, Krzysztof Selmaj, Lawrence Steinman, Amit Bar-Or, Xavier Montalban, Eva K Havrdová, James K Sheffield, Chahin Pachai, Chun-Yen Cheng, Jon V Riolo, Bruce Ac Cree.

Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials.

Mult Scler. 2025 Sep;31(10):1218-1230. doi: 10.1177/13524585251355842. Epub 2025 Jul 23. PubMed ID: 40698614

 

Further Information:

DOI: 10.1177/13524585251355842

Hans-Peter Hartung

Kategorie/n: NND-Publikationen